Used as a major metabolite of mycophenolic acid in the body, this compound plays a key role in immunosuppressive therapy, particularly in organ transplant recipients. It forms in the liver after mycophenolic acid administration and is eliminated through bile and urine. While inactive as an immunosuppressant itself, its presence affects the overall pharmacokinetics and clearance of the active drug. Monitoring levels of this metabolite helps optimize dosing and reduce toxicity risks in patients on immunosuppressive regimens.